219 related articles for article (PubMed ID: 34058457)
21. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test.
Moreira FA; Aguiar DC; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1466-71. PubMed ID: 16876926
[TBL] [Abstract][Full Text] [Related]
22. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
23. Use of cannabidiol in anxiety and anxiety-related disorders.
Skelley JW; Deas CM; Curren Z; Ennis J
J Am Pharm Assoc (2003); 2020; 60(1):253-261. PubMed ID: 31866386
[TBL] [Abstract][Full Text] [Related]
24. Effects of cannabidiol (CBD) on regional cerebral blood flow.
Crippa JA; Zuardi AW; Garrido GE; Wichert-Ana L; Guarnieri R; Ferrari L; Azevedo-Marques PM; Hallak JE; McGuire PK; Filho Busatto G
Neuropsychopharmacology; 2004 Feb; 29(2):417-26. PubMed ID: 14583744
[TBL] [Abstract][Full Text] [Related]
25. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.
Lee JLC; Bertoglio LJ; Guimarães FS; Stevenson CW
Br J Pharmacol; 2017 Oct; 174(19):3242-3256. PubMed ID: 28268256
[TBL] [Abstract][Full Text] [Related]
26. Considerations and Implications of Cannabidiol Use During Pregnancy.
Sarrafpour S; Urits I; Powell J; Nguyen D; Callan J; Orhurhu V; Simopoulos T; Viswanath O; Kaye AD; Kaye RJ; Cornett EM; Yazdi C
Curr Pain Headache Rep; 2020 Jun; 24(7):38. PubMed ID: 32524214
[TBL] [Abstract][Full Text] [Related]
27. Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders?
O'Sullivan SE; Stevenson CW; Laviolette SR
Cannabis Cannabinoid Res; 2021; 6(1):7-18. PubMed ID: 33614948
[TBL] [Abstract][Full Text] [Related]
28. The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event.
Bolsoni LM; Crippa JAS; Hallak JEC; Guimarães FS; Zuardi AW
Braz J Psychiatry; 2022; 44(3):298-307. PubMed ID: 35293520
[TBL] [Abstract][Full Text] [Related]
29. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study.
Spinella TC; Stewart SH; Naugler J; Yakovenko I; Barrett SP
Psychopharmacology (Berl); 2021 Jul; 238(7):1965-1977. PubMed ID: 33813611
[TBL] [Abstract][Full Text] [Related]
30. Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool.
Kwee CM; van Gerven JM; Bongaerts FL; Cath DC; Jacobs G; Baas JM; Groenink L
J Psychopharmacol; 2022 Dec; 36(12):1299-1314. PubMed ID: 36239014
[TBL] [Abstract][Full Text] [Related]
31. Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism.
Zieba J; Sinclair D; Sebree T; Bonn-Miller M; Gutterman D; Siegel S; Karl T
Pharmacol Biochem Behav; 2019 Jun; 181():93-100. PubMed ID: 31063743
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: A systematic review.
Rodrigues LA; Caroba MES; Taba FK; Filev R; Gallassi AD
Pharmacol Biochem Behav; 2020 Sep; 196():172982. PubMed ID: 32645315
[TBL] [Abstract][Full Text] [Related]
33. Anxiolytic effects of endocannabinoid enhancing compounds: A systematic review and meta-analysis.
Kwee CMB; Leen NA; Van der Kamp RC; Van Lissa CJ; Cath DC; Groenink L; Baas JMP
Eur Neuropsychopharmacol; 2023 Jul; 72():79-94. PubMed ID: 37094409
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial.
Crippa JAS; Zuardi AW; Guimarães FS; Campos AC; de Lima Osório F; Loureiro SR; Dos Santos RG; Souza JDS; Ushirohira JM; Pacheco JC; Ferreira RR; Mancini Costa KC; Scomparin DS; Scarante FF; Pires-Dos-Santos I; Mechoulam R; Kapczinski F; Fonseca BAL; Esposito DLA; Pereira-Lima K; Sen S; Andraus MH; Hallak JEC;
JAMA Netw Open; 2021 Aug; 4(8):e2120603. PubMed ID: 34387679
[TBL] [Abstract][Full Text] [Related]
35. Safety and side effects of cannabidiol, a Cannabis sativa constituent.
Bergamaschi MM; Queiroz RH; Zuardi AW; Crippa JA
Curr Drug Saf; 2011 Sep; 6(4):237-49. PubMed ID: 22129319
[TBL] [Abstract][Full Text] [Related]
36. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
Hahn B
Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
[TBL] [Abstract][Full Text] [Related]
37. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S; Kloiber S; Le Foll B
Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
[TBL] [Abstract][Full Text] [Related]
38. Cannabidiol-based natural health products for companion animals: Recent advances in the management of anxiety, pain, and inflammation.
Yu CHJ; Rupasinghe HPV
Res Vet Sci; 2021 Nov; 140():38-46. PubMed ID: 34391060
[TBL] [Abstract][Full Text] [Related]
39. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze.
Guimarães FS; de Aguiar JC; Mechoulam R; Breuer A
Gen Pharmacol; 1994 Jan; 25(1):161-4. PubMed ID: 7913072
[TBL] [Abstract][Full Text] [Related]
40. Cannabidiol in Anxiety and Sleep: A Large Case Series.
Shannon S; Lewis N; Lee H; Hughes S
Perm J; 2019; 23():18-041. PubMed ID: 30624194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
